A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia

p15INK4B, a cyclin-dependent kinase inhibitor, has been recognized as a tumor suppressor. Loss of or methylation of the p15INK4B gene in chronic myeloid leukemia (CML) cells enhances myeloid progenitor formation from common myeloid progenitors. Therefore, we examined the effects of overexpressed p15INK4B on proliferation and apoptosis of CML cells. Overexpression of p15INK4B inhibited the growth of K562 cells by downregulation of cyclin-dependent kinase 4 (CDK4) and cyclin D1 expression. Overexpression of p15INK4B also induced apoptosis of K562 cells by upregulating Bax expression and downregulating Bcl-2 expression. Overexpression of p15INK4B together with STI571 (imatinib) or BCR-ABL1 small interfering RNA (siRNA) also enhanced growth inhibition and apoptosis induction of K562 cells. The enhanced effect was also mediated by reduction of cyclin D1 and CDK4 and regulation of Bax and Bcl-2. In conclusion, our study may provide new insights into the role of p15INK4B in CML and a potential therapeutic target for overcoming tyrosine kinase inhibitor resistance in CML.

Involvement of Src Family Tyrosine Kinase in Apoptosis of Human Neutrophils Induced by Protozoan Parasite Entamoeba histolytica

Tyrosine kinases are one of the most important regulators for intracellular signal transduction related to inflammatory responses. However, there are no reports describing the effects of tyrosine kinases on neutrophil apoptosis induced by Entamoeba histolytica. In this study, isolated human neutrophils from peripheral blood were incubated with live trophozoites in the presence or absence of tyrosine kinase inhibitors. Entamoeba-induced receptor shedding of CD16 and PS externalization in neutrophils were inhibited by pre-incubation of neutrophils with the broad-spectrum tyrosine kinase inhibitor genistein or the Src family kinase inhibitor PP2. Entamoeba-induced ROS production was also inhibited by genistein or PP2. Moreover, genistein and PP2 blocked the phosphorylation of ERK and p38 MAPK in neutrophils induced by E. histolytica. These results suggest that Src tyrosine kinases may participate in the signaling event for ROS-dependent activation of MAPKs during neutrophil apoptosis induced by E. histolytica.

[Study of degradation factors of rosuvastatin calcium in order to enhance its stability]

The aim of the study is to find the best stability conditions for Rosuvastatin calcium. The study also aimed to ensure that Rosuvastatin analytical method is capable of separating it from its degradation products during stability tests. The stability of Rosuvastatin solution was studied when exposed to accelerated conditions in order to obtain its degradation products, these conditions included the addition of concentrated HCI, sodium hydroxide and hydrogen peroxide associated with high temperature as high as 90°C. The effect of light on stability of Rosuvastatin was also studied by exposing Rosuvastatin solutions to light for 24 hours without additive. The study was also carried on three series were conducted in the dark: The first series was carried out without any additive under temps 30, 40, 60 and 90°C and stored for 24 hours. The second series was conducted in the dark under the same temps with sodium hydroxide as an additive. The third one was incubated under the same conditions, with calcium ascorbate as an additives. The studied solutions were analyzed using HPLC. Equal quantities of 20 micro L of each solution were injected into HPLC. Rosuvastatin and its degradation products were analyzed on a C18 [250 mm x 4.6 mm] column octadecyl, using a mobile phase composed of acetonytril 25 parts, methanol 34 parts, water 4 parts, and one part of 3 ethylamine. The pH was adjusted with acetic acid to 4.5. The samples were monitored using UV detector at 240 nm with a Flow Rate of 1 ml/ min. The method showed good resolution for Rosuvastatin peak from the peaks of its degradation products. The results indicated that the proposed method is stability-indicating and could be used in stability tests. It was concluded that the most stable solutions included calcium ascorbate and sodium hydroxide. Light caused higher deterioration of Rosuvastatin; than high temperatures which showed less deterioration of Rosuvastatin solutions

General metabolism of the dimorphic and pathogenic fungus Paracoccidioides brasiliensis

Annotation of the transcriptome of the dimorphic fungus Paracoccidioides brasiliensis has set the grounds for a global understanding of its metabolism in both mycelium and yeast forms. This fungus is able to use the main carbohydrate sources, including starch, and it can store reduced carbons in the form of glycogen and trehalose; these provide energy reserves that are relevant for metabolic adaptation, protection against stress and infectivity mechanisms. The glyoxylate cycle, which is also involved in pathogenicity, is present in this fungus. Classical pathways of lipid biosynthesis and degradation, including those of ketone body and sterol production, are well represented in the database of P. brasiliensis. It is able to synthesize de novo all nucleotides and amino acids, with the sole exception of asparagine, which was confirmed by the fungus growth in minimal medium. Sulfur metabolism, as well as the accessory synthetic pathways of vitamins and co-factors, are likely to exist in this fungus.

Molecular biology and biochemistry of malarial parasite pyrimidine biosynthetic pathway.

Metabolic pathways in the malarial parasite are markedly different from the host, eg, hemoglobin, fatty acids, folate and nucleic acids. Understanding of metabolic function will illuminate new chemotherapeutic targets for drug development, including the identification of target(s) for drugs in current use. The parasite-contained pyrimidine biosynthetic pathway is essential for growth and development in the human host. Plasmodium falciparum carbonic anhydrase, producing HCO3- as a pyrimidine precursor, was identified as alpha- type and the encoded gene was cloned and sequenced. The first six enzymes, catalyzing the conversion of HCO3-, ATP, L-aspartate and L-glutamine to uridine 5'-monophosphate (UMP), were partially characterized. The genes encoding these enzymes were identified in order, from the first to the sixth step, as CPSII (carbamyl phosphate synthase II), ATC (aspartate transcarbamylase), DHO (dihydroorotase), DHOD (dihydroorotate dehydrogenase, DHOD), OPRT (orotate phosphoribosyltransferase, OPRT), and OMPDC (orotidine 5'-monophosphate decarboxylase, OMPDC). Unlike its analogous parasitic protozoan, Trypanosoma, the organization of the malarial genes was not an operon-like cluster. The CPSII, DHO and OPRT genes were conserved to bacterial counterparts, whereas the ATC, DHOD and OMPDC were mosaic variations. The data support the mosaic pyrimidine pathway in the malarial parasite. The human host had five enzymes out of the six associated into two different multifunctional proteins, in that a single gene CPSII-ATC-DHO encoded the first three enzymes, and another gene OPRT-OMPDC encoded the last two enzymes. In the malarial parasite, the CPSII and ATC were not characterized. The DHO was partially characterized in Plasmodium berghei. The DHOD was well characterized in both P. falciparum and P. berghei. It was functionally expressed in Escherichia coli. The physical and kinetic properties of the recombinant pfDHOD were similar to the native enzyme. The OPRT and OMPDC were also partially characterized. These lines of evidence indicate that the malarial pyrimidine enzymes are mono-functional forms. In addition, the enzymatic activities inter-converting uracil, uridine and UMP of the pyrimidine salvage pathway, were demonstrated, and the gene encoding uridine phosphorylase was cloned. Our results suggest that the pyrimidine enzymes are possible new drug targets.

Ultrastructural studies on nodules induced by pyrimidine auxotrophs of Sinorhizobium meliloti.

Twenty three pyrimidine auxotrophs of Sinorhizobium meliloti Rmd201 were generated by random mutagenesis with transposon Tn5. On the basis of biochemical characters these auxotrophic mutants were classified into car, pyrC and pyrE/pyrF categories. All auxotrophs induced white nodules which were ineffective in nitrogen fixation. Light and electron microscopic studies revealed that the nodules induced by pyrC mutants were more developed than the nodules of car mutants. Similarly the nodules induced by pyrE/pyrF mutants had more advanced structural features than the nodules of pyrC mutants. The nodule development in case of pyrE/pyrF mutants was not to the extent observed in the parental strain. These results indicated that some of the intermediates and/or enzymes of pyrimidine biosynthetic pathway of S. meliloti play a key role in bacteroidal transformation and nodule development.

Metabolic enzymes as potential drug targets in Plasmodium falciparum.

Plasmodium falciparum causes the most severe form of malaria that is fatal in many cases. Emergence of drug resistant strains of P. falciparum requires that new drug targets be identified. This review considers in detail enzymes of the glycolytic pathway, purine salvage pathway, pyrimidine biosynthesis and proteases involved in catabolism of haemoglobin. Structural features of P. falciparum triosephosphate isomerase which could be exploited for parasite specific drug development have been highlighted. Utility of P. falciparum hypoxanthine-guanine-phosphoribosyltransferase, adenylosuccinate synthase, dihydroorotate dehydrogenase, thymidylate synthase-dihydrofolate reductase, cysteine and aspartic proteases have been elaborated in detail. The review also briefly touches upon other potential targets in P. falciparum.

Development of inhibitors of pyrimidine metabolism

Benzylacyclouridines were developed as specific and potent competitive inhibitors of uridine phosphorylase with Ki values in the nanomolar range. These compounds have no activity against thymidine phosphorylase, uridine kinase, thymidine kinase and orotate phosphoribosyltransferase. Benzylacyclouridines potentiate the chemotherapeutic effect of FdUrd. Coadministration of uridine phosphorylase inhibitor with FdUrd caused selective toxicity against tumors with low or no thymidine phosphorylase, but not against the host tissues which have thymidine phosphorylase, and thus retain the capacity to cleave FdUrd, and hence overcome its toxicity. There are distinct differences between uridine phosphorylase and thymidine phosphorylase. Benzylacyclouridines competitively inhibit the nucleoside transport of mammalian cells. The structure-activity relationship of inhibitors of uridine phosphorylase showed that a large hydrophobic pocket exists where C-5 of uracil binds, and that it is necessary to have the 3'-hydroxyl group and syn-configuration around the N-glycosidic bond for the nucleosides or their analogs to bind. Dihydrouracil dehydrogenase was found to be widely distributed among mammalian cells, where it was previously believed to be present only in the liver and the kidney. The structure-activity relationship of its inhibitors revealed benzyloxybenzyluracil and 2,6-pyridinediol as most potent. Also identified for orotate phosphoribosyltransferase was 2,4-pyridinediol.

Development of inhibitors of pyrimidine metabolism

Benzylacyclouridines were developed as specific and potent competitive inhibitors of uridine phosphorylase with Ki values in the nanomolar range. These compounds have no activity against thymidine phosphorylase, uridine kinase, thymidine kinase and orotate phosphoribosyltransferase. Benzylacyclouridines potentiate the chemotherapeutic effect of FdUrd. Coadministration of uridine phosphorylase inhibitor with FdUrd caused selective toxicity against tumors with low or no thymidine phosphorylase, but not against the host tissues which have thymidine phosphorylase, and thus retain the capacity to cleave FdUrd, and hence overcome its toxicity. There are distinct differences between uridine phosphorylase and thymidine phosphorylase. Benzylacyclouridines competitively inhibit the nucleoside transport of mammalian cells. The structure-activity relationship of inhibitors of uridine phosphorylase showed that a large hydrophobic pocket exists where C-5 of uracil binds, and that it is necessary to have the 3'-hydroxyl group and syn-configuration around the N-glycosidic bond for the nucleosides or their analogs to bind. Dihydrouracil dehydrogenase was found to be widely distributed among mammalian cells, where it was previously believed to be present only in the liver and the kidney. The structure-activity relationship of its inhibitors revealed benzyloxybenzyluracil and 2,6-pyridinediol as most potent. Also identified for orotate phosphoribosyltransferase was 2,4-pyridinediol.

Ansiolíticos seletivos / Selective ampiolytics

Embora os ansiolíticos benzodiazepínicos (BDZ) sejam clinicamente efetivos, causam sonolência e ataxia, intensificam os efeitos do etanol e outros agentes depressores e podem induzir dependência psicológica e fisiológica. Na tentativa de eliminar esses inconvenientes, tem-se procurado desenvolver compostos ânsio-seletivos. Uma vertente dessas pesquisas trabalha com ligantes dos receptores BDZ que atuam como agonistas parciais, mantendo o efeito ansiolítico, porém perdendo o efeito sedativo. Duas outras linhas de trabalho investigam compostos que näo interagem com os receptores BDZ, parecendo atuar diretamente sobre a neurotransmissäo serotonérgica. A primeira desenvolveu antagonistas seletivos dos receptores tipo S2 da serotonina (5-HT), como a ritanserina e a piremperona. A segunda concentra-se em análogos estruturais do aloperidol, que perderam a afinidade pelos receptores da dopamina e passaram a atuar como agonistas seletivos do subtipo S1A dos receptores da 5-HT. A este grupo pertencem a buspirona e análogos. Compostos de cada uma das três classes acima apresentaram atividade ansiolítica em modelos animais de ansiedade, bem como efeito terapêutico comparável ao dos BDZ, porém com menos sedaçäo, em ensaios clínicos duplo-cego. Porém, somente a buspirona foi recentemente liberada para uso médico. Além de ser menos sedativa que os BDZ, a buspirona näo potencializa os efeitos do etanol e näo revelou potencial de gerar dependência em voluntários humanos. Entretanto, ainda é prematuro concluir sobre sua superioridade terapêutica em relaçäo aos ansiolíticos BDZ clássicos